Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Director Sells 34,947 Shares of Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 34,947 shares of the stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $1.21, for a total value of $42,285.87. Following the transaction, the director owned 3,787,474 shares in the company, valued at approximately $4,582,843.54. This trade represents a 0.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Luke Evnin also recently made the following trade(s):

• On Wednesday, November 5th, Luke Evnin sold 30,774 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.22, for a total value of $37,544.28.
• On Tuesday, November 4th, Luke Evnin sold 90,164 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.22, for a total value of $110,000.08.
• On Monday, November 3rd, Luke Evnin sold 60,369 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.29, for a total value of $77,876.01.
• On Friday, October 31st, Luke Evnin sold 73,192 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.28, for a total value of $93,685.76.
• On Thursday, October 30th, Luke Evnin sold 55,795 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.43, for a total value of $79,786.85.
• On Wednesday, October 29th, Luke Evnin sold 86,154 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.55, for a total value of $133,538.70.
• On Tuesday, October 28th, Luke Evnin sold 44,327 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.64, for a total value of $72,696.28.
• On Monday, October 27th, Luke Evnin sold 46,664 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.72, for a total value of $80,262.08.

Werewolf Therapeutics Stock Performance

Shares of NASDAQ HOWL traded down $0.02 during trading hours on Thursday, reaching $1.20. 647,728 shares of the stock were exchanged, compared to its average volume of 891,846. The firm has a market capitalization of $58.25 million, a price-to-earnings ratio of -0.74 and a beta of 0.72. Werewolf Therapeutics, Inc. has a 52 week low of $0.60 and a 52 week high of $2.41. The company has a debt-to-equity ratio of 0.73, a quick ratio of 5.30 and a current ratio of 3.87. The stock’s fifty day simple moving average is $1.61 and its 200 day simple moving average is $1.32.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03. Sell-side analysts predict that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current year.

Institutional Investors Weigh In On Werewolf Therapeutics

A number of large investors have recently modified their holdings of the business. MPM Bioimpact LLC boosted its holdings in shares of Werewolf Therapeutics by 0.9% in the 1st quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock valued at $2,341,000 after purchasing an additional 20,799 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Werewolf Therapeutics by 33.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company’s stock valued at $93,000 after acquiring an additional 23,852 shares during the last quarter. MPM Asset Management LLC lifted its stake in shares of Werewolf Therapeutics by 0.6% in the 1st quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock valued at $4,189,000 after acquiring an additional 25,688 shares during the last quarter. Quadrature Capital Ltd bought a new position in shares of Werewolf Therapeutics in the 2nd quarter valued at $28,000. Finally, Bank of America Corp DE lifted its stake in shares of Werewolf Therapeutics by 1.2% in the 2nd quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock valued at $2,321,000 after acquiring an additional 25,882 shares during the last quarter. Institutional investors and hedge funds own 64.84% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on HOWL. Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, October 8th. Citigroup reissued a “buy” rating on shares of Werewolf Therapeutics in a research report on Monday, August 25th. Zacks Research raised Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 16th. Bank of America reduced their price target on Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating on the stock in a research report on Monday, August 25th. Finally, JMP Securities reduced their price target on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 21st. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Werewolf Therapeutics has an average rating of “Moderate Buy” and an average target price of $8.00.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.